Compare Gilead Sciences, Inc. (GILD) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Zeta Global Holdings Corp — how do they compare? Gilead Sciences, Inc. trades at $150.87 (market cap $182.40B), while Zeta Global Holdings Corp trades at $33.18 (market cap $8.29B). The key difference: Gilead Sciences, Inc. is far larger — about 22× Zeta Global Holdings Corp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Zeta Global Holdings Corp for 19 Days on average.
| GILD | ZETA | |
|---|---|---|
Market Cap | $182.40B | $8.29B |
Volume | 4,469,821 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $155.80 | $33.74 |
52-Week Low | $116.74 | $14.55 |
Typical Hold Time | 111 Days | 19 Days |
Enterprise Value | $205.46B | $8.18B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
ZETA trades at $33.63, down 0.33% on the day, showing resilience near its 52-week high territory. The stock maintains strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent expansion into the UK market and growing AI platform adoption support the positive sentiment, though negative net income margins and elevated valuation metrics warrant caution.
The outlook remains cautiously optimistic with 75% analyst buy ratings and a $32.40 consensus target. Key opportunities include accelerating revenue growth and AI-driven customer expansion, while risks involve negative profitability, high valuation multiples, and potential insider fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
